Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance

Borghesi, Marco; Bianchi, Lorenzo; Barbaresi, U.; Vagnoni, Valerio; Corcioni, Beniamino; Gaudiano, Caterina; Fiorentino, Michelangelo; Giunchi, Francesca; Chessa, F.; Garofalo, Marco; Bertaccini, Alessandro; Angelini, Stefano; Ercolino, Amelio; Casablanca, Carlo; Droghetti, Matteo; Golfieri, Rita; Schiavina, Riccardo

doi:10.23736/s2724-6051.20.03758-3

Cited by 27 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several recent studies have demonstrated the advantage of FBx over SBx in the detection of csPCa [11,[26][27][28][29][30][31]. In 2018, Kasivisvanathan et al reported the randomized controlled trial of 500 men with PCa suspicion, randomly assigned for FBx or SBx-the PRECISION trial [11].…”

Section: Multiparametric Mri In the Prostate Cancer Diagnosticsmentioning

confidence: 99%

Alternatives for MRI in Prostate Cancer Diagnostics—Review of Current Ultrasound-Based Techniques

Gurwin

Kowalczyk

Knecht-Gurwin

et al. 2022

Cancers

View full text Add to dashboard Cite

The purpose of this review is to present the current role of ultrasound-based techniques in the diagnostic pathway of prostate cancer (PCa). With overdiagnosis and overtreatment of a clinically insignificant PCa over the past years, multiparametric magnetic resonance imaging (mpMRI) started to be recommended for every patient suspected of PCa before performing a biopsy. It enabled targeted sampling of the suspicious prostate regions, improving the accuracy of the traditional systematic biopsy. However, mpMRI is associated with high costs, relatively low availability, long and separate procedure, or exposure to the contrast agent. The novel ultrasound modalities, such as shear wave elastography (SWE), contrast-enhanced ultrasound (CEUS), or high frequency micro-ultrasound (MicroUS), may be capable of maintaining the performance of mpMRI without its limitations. Moreover, the real-time lesion visualization during biopsy would significantly simplify the diagnostic process. Another value of these new techniques is the ability to enhance the performance of mpMRI by creating the image fusion of multiple modalities. Such models might be further analyzed by artificial intelligence to mark the regions of interest for investigators and help to decide about the biopsy indications. The dynamic development and promising results of new ultrasound-based techniques should encourage researchers to thoroughly study their utilization in prostate imaging.

show abstract

Section: Multiparametric Mri In the Prostate Cancer Diagnosticsmentioning

confidence: 99%

Alternatives for MRI in Prostate Cancer Diagnostics—Review of Current Ultrasound-Based Techniques

Gurwin

Kowalczyk

Knecht-Gurwin

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“… 75 Additionally, a study comparing fusion-targeted biopsy and systematic biopsy in patients with a previous negative biopsy and patients under active surveillance (AS) found that fusion-targeted biopsy detected a significantly higher rate of csPCa than systematic biopsy among patients with a previous negative biopsy (41.3% vs 27%, p=0.038) but report no significant difference in overall PCa (50% vs 73.1%) or csPCa (30.8% vs 26.9%, p=0.705) detection for patients under AS. 76 …”

Section: Comparison Of Trus To Multiparametric Mrimentioning

confidence: 99%

Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications

Panzone¹,

Byler²,

Bratslavsky³

et al. 2022

CMAR

View full text Add to dashboard Cite

“…Several methods are used for detecting PCa, such as determining prostate-specific antigen (PSA) levels, digital rectal examination (DRE), magnetic resonance imaging (MRI), and ultrasound. However, PSA or DRE has a high false positive rate that leads to a large number of unnecessary systematic biopsies (SBs) [ 2 ]. MRI offers better anatomical resolution and high accuracy in PCa diagnosis compared with other methods, but MRI guide TB (in-bore TB) is rather time-consuming [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer

2022

View full text Add to dashboard Cite

Objective To evaluate the combined efficacy of multiparametric ultrasonography (mpUS) and multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI-TRUS) fusion for detecting clinically significant prostate cancer (csPCa). Methods From November 2019 to September 2021, biopsy-naïve patients underwent mpMRI-TRUS fusion imaging combined with mpUS-guided targeted biopsies (TB) and systematic biopsies (SB). To further evaluate the additional diagnostic value of mpUS, the imaging features of 202 focus obtained from fusion imaging were assessed. The diagnostic accuracies of mpMRI-TRUS fusion imaging and the combination of mpMRI-TRUS fusion imaging with mpUS for csPCa were comparatively evaluated. Results A total of 202 prostate lesions (160 patients) were included in the final analysis, of which 105 were csPCa, 16 were ciPCa, and 81 were noncancerous. The median patient age was 69 (65–73) years and the median tPSA was 22.07 (11.22–62.80) ng/mL. For csPCa, the detection rate of TB was higher than that of SB (50.0% vs. 45.5%, p < 0.05). The imaging characteristics of mpUS in the PCa and non-PCa groups were significantly different (p < 0.001). When compared with mpMRI-TRUS fusion imaging, the positive predictive value, false positive rate, and area under the curve (AUC) of csPCa diagnosis by mpMRI-TRUS fusion imaging combined with mpUS increased by 11.30%, decreased by 19.58%, and increased from 0.719 to 0.770 (p < 0.05), respectively. Conclusion TB can improve the detection rate of csPCa and hence can be effectively used in the diagnosis and risk assessment of csPCa. The mpUS-enriched valuable diagnostic information for mpMRI-TRUS fusion imaging and their combination showed a higher diagnostic value for csPCa, which can guide subsequent clinical treatment.

show abstract

Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance

Cited by 27 publications

References 37 publications

Alternatives for MRI in Prostate Cancer Diagnostics—Review of Current Ultrasound-Based Techniques

Alternatives for MRI in Prostate Cancer Diagnostics—Review of Current Ultrasound-Based Techniques

Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications

The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer

Contact Info

Product

Resources

About